...the sale of 1.6 million shares at the same price in a private placement to Genextra S.p.A....

...the sale of 1.6 million shares at the same price in a private placement to Genextra S.p.A....

...shares at $33.01 for a postmoney valuation of $622.6 million. Intercept's major early investors were Genextra S.p.A....
...are worth $770 million, representing a 30x multiple, not counting shares it has already sold. Genextra...
...are worth $2.6 billion, representing a 32x multiple, not counting shares it has already sold. Genextra...

...Intercept shareholders OrbiMed Advisors and Genextra S.p.A. (Milan, Italy) plan to sell 1.5 million shares of Intercept...
...The shareholders expect to receive $93.8 million through the sale. BofA Merrill Lynch is underwriter. Genextra's...

...Dutch Phase I trial to evaluate single ascending-doses IV GNX-5086 in about 33 healthy volunteers. Genextra S.p.A....

...Drug delivery, Neurology Date completed: 7/31/13 Type: Venture financing Raised: €15 million ($19.9 million) Investors: Genextra...

...EryDel S.p.A. , Urbino, Italy Business: Drug delivery, Neurology Appointed: Lorenzo Tallargio, CEO of Genextra S.p.A. WIR Staff...

...led by new investor Genextra S.p.A. , with participation from existing investors Innogest and Focus Gestioni. Genextra's...

...Business: Hepatic, Endocrine/Metabolic Date completed: 8/9/12 Type: Venture financing Raised: $30 million Investors: OrbiMed Advisors; Genextra WIR...

...N.Y.) raised $30 million in a series C round led by OrbiMed Advisors. Existing investor Genextra S.p.A....